These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 17992394)
1. Tissue microarrays for testing basal biomarkers in familial breast cancer cases. Dufloth RM; Matos I; Schmitt F; Zeferino LC Sao Paulo Med J; 2007 Jul; 125(4):226-30. PubMed ID: 17992394 [TBL] [Abstract][Full Text] [Related]
2. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Dabbs DJ; Chivukula M; Carter G; Bhargava R Mod Pathol; 2006 Nov; 19(11):1506-11. PubMed ID: 16941011 [TBL] [Abstract][Full Text] [Related]
3. P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. Paredes J; Lopes N; Milanezi F; Schmitt FC Virchows Arch; 2007 Jan; 450(1):73-80. PubMed ID: 17123107 [TBL] [Abstract][Full Text] [Related]
4. Prognostic markers in triple-negative breast cancer. Rakha EA; El-Sayed ME; Green AR; Lee AH; Robertson JF; Ellis IO Cancer; 2007 Jan; 109(1):25-32. PubMed ID: 17146782 [TBL] [Abstract][Full Text] [Related]
5. Negative/low HER2 expression alone or combined with E-cadherin positivity is predictive of better prognosis in patients with breast carcinoma. Karray-Chouayekh S; Trifa F; Khabir A; Sellami-Boudawara T; Frikha M; Gargouri A; Mokdad-Gargouri R Histol Histopathol; 2012 Mar; 27(3):377-85. PubMed ID: 22237715 [TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain. Werling RW; Hwang H; Yaziji H; Gown AM Am J Surg Pathol; 2003 Jan; 27(1):82-90. PubMed ID: 12502930 [TBL] [Abstract][Full Text] [Related]
7. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Livasy CA; Karaca G; Nanda R; Tretiakova MS; Olopade OI; Moore DT; Perou CM Mod Pathol; 2006 Feb; 19(2):264-71. PubMed ID: 16341146 [TBL] [Abstract][Full Text] [Related]
8. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Matos I; Dufloth R; Alvarenga M; Zeferino LC; Schmitt F Virchows Arch; 2005 Oct; 447(4):688-94. PubMed ID: 16012853 [TBL] [Abstract][Full Text] [Related]
9. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Laakso M; Loman N; Borg A; Isola J Mod Pathol; 2005 Oct; 18(10):1321-8. PubMed ID: 15990899 [TBL] [Abstract][Full Text] [Related]
10. p63 Staining of myoepithelial cells in breast fine needle aspirates: a study of its role in differentiating in situ from invasive ductal carcinomas of the breast. Reis-Filho JS; Milanezi F; Amendoeira I; Albergaria A; Schmitt FC J Clin Pathol; 2002 Dec; 55(12):936-9. PubMed ID: 12461063 [TBL] [Abstract][Full Text] [Related]
11. The relationship between p63 and p53 expression in normal and neoplastic breast tissue. Ribeiro-Silva A; Zambelli Ramalho LN; Britto Garcia S; Zucoloto S Arch Pathol Lab Med; 2003 Mar; 127(3):336-40. PubMed ID: 12653579 [TBL] [Abstract][Full Text] [Related]
12. Comedo-DCIS is a precursor lesion for basal-like breast carcinoma: identification of a novel p63/Her2/neu expressing subgroup. Shekhar MP; Kato I; Nangia-Makker P; Tait L Oncotarget; 2013 Feb; 4(2):231-41. PubMed ID: 23548208 [TBL] [Abstract][Full Text] [Related]
13. Phenotypic and Functional Characterization of Ductal Carcinoma In Situ-Associated Myoepithelial Cells. Rohilla M; Bal A; Singh G; Joshi K Clin Breast Cancer; 2015 Oct; 15(5):335-42. PubMed ID: 25700939 [TBL] [Abstract][Full Text] [Related]
14. p63 expression is associated with high histological grade, aberrant p53 expression and TP53 mutation in HER2-positive breast carcinoma. Guo S; Wang Y; Rohr J; Shang L; Ma J J Clin Pathol; 2021 Oct; 74(10):641-645. PubMed ID: 32873702 [TBL] [Abstract][Full Text] [Related]
15. P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer. Turashvili G; McKinney SE; Goktepe O; Leung SC; Huntsman DG; Gelmon KA; Los G; Rejto PA; Aparicio SA Mod Pathol; 2011 Jan; 24(1):64-81. PubMed ID: 20852590 [TBL] [Abstract][Full Text] [Related]
16. Basal-like immunophenotype markers and prognosis in early breast cancer. Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B Tumori; 2010; 96(6):966-70. PubMed ID: 21388060 [TBL] [Abstract][Full Text] [Related]
17. Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast. Grenier J; Soria JC; Mathieu MC; Andre F; Abdelmoula S; Velasco V; Morat L; Besse B; Dunant A; Spielmann M; Delaloge S Anticancer Res; 2007; 27(1B):547-55. PubMed ID: 17348440 [TBL] [Abstract][Full Text] [Related]
18. p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. Ribeiro-Silva A; Ramalho LN; Garcia SB; Brandão DF; Chahud F; Zucoloto S Histopathology; 2005 Nov; 47(5):458-66. PubMed ID: 16241993 [TBL] [Abstract][Full Text] [Related]
19. Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin. Ben Hamida A; Labidi IS; Mrad K; Charafe-Jauffret E; Ben Arab S; Esterni B; Xerri L; Viens P; Bertucci F; Birnbaum D; Jacquemier J BMC Cancer; 2008 Jan; 8():28. PubMed ID: 18230143 [TBL] [Abstract][Full Text] [Related]
20. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. Rakha EA; Putti TC; Abd El-Rehim DM; Paish C; Green AR; Powe DG; Lee AH; Robertson JF; Ellis IO J Pathol; 2006 Mar; 208(4):495-506. PubMed ID: 16429394 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]